Investing
US FDA panel votes against Merck’s chronic cough drug
© Reuters. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
(Reuters) – The U.S. health regulator’s advisers on Friday did not recommend Merck’s drug for the treatment of chronic cough.
The FDA panel voted 12 to 1 that the data presented does not demonstrate substantial evidence of effectiveness of the oral tablet, gefapixant, for the treatment of refractory or unexplained chronic cough.
Read the full article here